Torsten Schönberger

Torsten Schönberger

Auto-generated profile, based on publicly available information

Torsten Schönberger

Federal Criminal Police Office Forensic Science Institute Wiesbaden Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2022 in Drug Testing and Analysis
Verified
Journal Article
Open access
BPBenedikt Pulver
Benedikt Pulver
SFSvenja Fischmann
Svenja Fischmann
FWFolker Westphal
Folker Westphal
TSTorsten Schönberger
Torsten Schönberger
JSJan Schäper
Jan Schäper
MPMichael Pütz
Michael Pütz
Novel substances for which none or limited analytical data are available constitute a challenge for police and customs forensic laboratories. The time‐consuming process of structural elucidation and acquisition of analytical data has been centralized in the ADEBAR project in Germany, co‐funded since 2017 by the EU's Internal Security Fund. The project aims to comprehensively characterize substances relevant for forensic‐toxicological casework within the analytical competence network. The analytical datasets are distributed digitally through European and (inter)national channels. Additionally, pharmacological evaluation allows for estimating in vivo potency and potential harm required as scientific evidence for legislative amendments. The ADEBAR project contributes to the availability of analytical data on new substances relevant to the daily work of police and customs laboratories. Since the inception of the ADEBAR project, 549 samples have been registered, and 302 substance reports notified to the EMCDDA, including numerous spectrometric and spectroscopic data. In addition, 3,619 mass spectra have been accumulated in ADEBAR mass spectra databases. A central institution for the structure elucidation and acquisition of valid, high‐quality analytical data for police and customs forensic laboratories and forensic medicine institutes is important in the future because there does not seem to be an end to the dynamic of novel NPS appearing on the drug market.

9 April 2022 in Drug Testing and Analysis
Verified
Journal Article
Closed access
BPBenedikt Pulver
Benedikt Pulver
TSTorsten Schönberger
Torsten Schönberger
DWDiana Weigel
Diana Weigel
MKMatthias Köck
Matthias Köck
YEYvonne Eschenlohr
Yvonne Eschenlohr
FWFolker Westphal
Folker Westphal


9 January 2023 in Drug Testing and Analysis
Verified
Journal Article
Open access
BPBenedikt Pulver
Benedikt Pulver
JRJan Riedel
Jan Riedel
TSTorsten Schönberger
Torsten Schönberger
SHSebastian Halter
Sebastian Halter
TLTobias Lucas
Tobias Lucas
Volker AuwärterVolker Auwärter
Volker Auwärter
Synthetic cannabinoid receptor agonists (SCRAs) are distributed on the drug market to produce THC‐like effects while evading routine drug testing and legislation. The cyclobutylmethyl (CBM) and norbornylmethyl (NBM) side chain specifically circumvented the German legislation and led to the emergence of exploratory SCRAs in 2019–2021. The NBM SCRAs were detected post‐amendment of the new psychoactive substances act in 2020, which scheduled all CBM SCRAs. All six SCRAs are full agonists at the cannabinoid receptor 1 compared with Δ9‐tetrahydrocannabinol and CP‐55,940. The CBM SCRAs showed binding affinities of Ki: 29.4–0.65 nm and potencies of EC50: 483–40.1 nm (CBMICA << CBMINACA < CBMeGaClone). The norbornyl derivatives exhibited high affinities (Ki: 1.87–0.25 nm), with indazole being the most affine. Functional activity data confirmed that the indazole derivative tends to be the most potent of all three NBM SCRAs (EC50: 169–1.78 nm). The sterically demanding NBM side chain increased the affinity and activity of almost all core structures. Future studies should be conducted on similarly voluminous side chain moieties. The ‘life cycle’ of all SCRAs on the drug market was less than a year. Notably, Cumyl‐CBMICA was the most prevalent while also having the weakest cannabimimetic properties. Quantification of Cumyl‐CBMICA during peak consumption in late 2019 and early 2020 revealed an increase in the concentration on the herbal material, which, together with forum entries and blog posts, corroborates the low in vitro cannabimimetic properties. Seizure prevalence data indicate that almost all SCRAs continue to be identified in 2022, potentially due to remaining stocks.

23 November 2021 in Data in Brief
Verified
Journal Article
Open access
BPBenedikt Pulver
Benedikt Pulver
JRJan Riedel
Jan Riedel
TSTorsten Schönberger
Torsten Schönberger
MPMichael Pütz
Michael Pütz
JSJan Schäper
Jan Schäper
FWFolker Westphal
Folker Westphal
Synthetic cannabimimetics (SC) are a diverse group of new psychoactive substances with varying potency and harm potential. New SCs appear on the drug market every year, and reliable and correct identification of these new derivatives independent from the matrix relies on the availability of verified spectra. Three new synthetic cannabimimetics featuring a norbornyl methyl side chain and varying core structure elements were identified in different seizures and forms. Cumyl-BC[2.2.1]HpMeGaClone and Cumyl-BC[2.2.1]HpMINACA were laced onto herbal blends, whereas Cumyl-BC[2.2.1]HpMICA was seized as a pure solid powder. The data collection process involves a comprehensive set of orthogonal analytical techniques allowing for the unambiguous identification of the respective endo- and exo-isomers.